Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.

Glenn M ChertowPablo E PergolaYoussef M K FaragRajiv AgarwalSusan ArnoldGabriel BakoGeoffrey A BlockSteven BurkeFausto P CastilloAlan G JardineZeeshan KhawajaMark J KouryEldrin F LewisTim LinWenli LuoBradley J MaroniKunihiro MatsushitaPeter A McCulloughPatrick S ParfreyPrabir Roy-ChaudhuryMark J SarnakAmit SharmaBruce SpinowitzCarol TsengJames TumlinDennis L VargoKimberly A WaltersWolfgang C WinkelmayerJanet WittesKai-Uwe Eckardtnull null

Published in: The New England journal of medicine (2021)

Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO2TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).

Keyphrases

chronic kidney disease
end stage renal disease
small molecule
tyrosine kinase
replacement therapy
iron deficiency
smoking cessation